Patent · US Active

Rodent model of mood disorders

US11470828B2 · kind B2 · utility

0Cited by

2References

24Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Meghan Drummond Samuelson · Tarrytown, US
Brian Zambrowicz · Diemelstraße, US
Ka-Man Venus Lai · San Francisco, US
Charleen Hunt · Dumont, US
Susannah Brydges · Scarsdale, US
Andrew J. Murphy · Croton-on-Hudson, US
Claudia Gonzaga-Jauregui · Tarrytown, US
Jose F. Rojas · Newburgh, US
Nicole Alessandri-Haber · Rye, US
Robert Breese · Quakertown, US
Susan D. Croll · New Paltz, US

Key dates

Filing date	Jan 16, 2020
Grant date	Oct 18, 2022
Priority date	—
Expiry date	Mar 26, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA01K2267/0393
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.